{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Adverse Event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}],"title":"Prophylaxis"}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"Number of participants with reasons for hospitalization from JCARH125 administration","groups":[{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells expansion","id":"OG000","title":"Phase 2 600 x 10^6 Cells"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who received at least one infusion of JCARH125 with baseline and post-baseline assessment at the respective visit in phase 2 only as prespecified in the protocol","reportingStatus":"POSTED","timeFrame":"From JCARH125 infusion to up to approximately 61 months","title":"Reasons for Hospitalization From JCARH125 Administration in Phase 2","type":"SECONDARY","unitOfMeasure":"Participants"}